Healthcare Services

Orthobiologics Market Projected To Surpass $9.86 Billion By 2030 At 5.6% CAGR

June 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Expected Market Value Outlook For The Orthobiologics Market Through 2030?

The orthobiologics market has exhibited robust growth in recent years. Its value is projected to rise from $7.48 billion in 2025 to $7.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.1%. This historical expansion can be attributed to several factors, including the limited access to effective regenerative therapies, the increasing prevalence of musculoskeletal disorders, the growing adoption of surgical interventions such as spinal fusion, enhanced awareness of orthobiologics among orthopedic surgeons, and the early utilization of autografts and allografts in clinical practice.

The orthobiologics market is projected to experience robust expansion in the coming years, with its valuation anticipated to reach $9.86 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.6%. This projected growth is primarily driven by an expanding array of cellular and exosome-based orthobiologic products, heightened investment in tissue engineering and regenerative medicine, the increasing acceptance of minimally invasive and outpatient orthopedic procedures, a surging demand for customized and precise orthobiologic treatments, and the wider application of orthobiologics in dental and maxillofacial fields. Key developments foreseen during this period encompass the growing utilization of platelet-rich plasma (prp) and bone morphogenetic proteins (bmps), a rising reliance on synthetic bone substitutes for mending fractures and spinal fusion, a developing inclination towards cellular allografts and stem cell-based therapies, an intensified focus on minimally invasive orthopedic interventions, and a greater emphasis on quicker recovery times and better clinical results.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16139&type=smp

Which Core Factors Are Supporting The Expansion Of The Orthobiologics Market?

The increasing prevalence of road accidents and sports injuries is anticipated to fuel the expansion of the orthobiologics market. These incidents involve physical harm to individuals, frequently impacting the musculoskeletal system, and are often attributed to causes like distracted driving, speeding, and hazardous road conditions for accidents, alongside overuse, incorrect equipment, and insufficient training for sports injuries. Orthobiologics provide treatment by facilitating quicker and more effective healing of musculoskeletal tissues, diminishing inflammation, and enhancing the body’s inherent repair processes through the application of substances such as bone grafts, growth factors, stem cells, and platelet-rich plasma. As an illustration, a report from the Bureau of Infrastructure and Transport Research Economics (BITRE), an Australian government agency, stated that there were 1,340 road deaths in July 2025, signifying a 2.9% rise when compared to the 12 months ending July 2024. Therefore, the growing incidence of sports injuries and road accidents will propel the orthobiologics market.

How Is Segment Classification Applied In The Orthobiologics Market?

The orthobiologics market covered in this report is segmented –

1) By Product Type: Viscosupplements, Bone Growth Factors, Demineralized Bone Matrix, Synthetic Bone Substitutes, Cellular Allograft, Other Products

2) By Application: Spinal Fusion, Maxillofacial And Dental, Soft Tissue Repair, Reconstructive And Fracture Surgery, Other Applications

3) By End User: Hospitals, Orthopedic Clinics, Ambulatory Surgery Centers, Other End Users

Subsegments:

1) By Viscosupplements: Hyaluronic Acid Injections, Gel-Based Viscosupplements, Cross-linked Hyaluronic Acid

2) By Bone Growth Factors: Bone Morphogenetic Proteins (BMPs), Recombinant Human Bone Morphogenetic Proteins (rhBMPs), Platelet-Rich Plasma (PRP), Osteogenic Protein-1 (OP-1), Growth Factors For Bone Healing

3) By Demineralized Bone Matrix: DBM Grafts, DBM Putty, DBM Sponges, DBM Paste And Chips

4) By Synthetic Bone Substitutes: Calcium Phosphate-Based Substitutes, Calcium Sulfate-Based Substitutes, Tricalcium Phosphate (TCP), Hydroxyapatite (HA), Bioactive Glasses

5) By Cellular Allograft: Osteocellular Allografts, Mesenchymal Stem Cells (MSCs) Allografts, Bone Marrow-Derived Cellular Allografts, Adipose Tissue-Derived Cellular Allografts

6) By Other Products: Autografts, Collagen-Based Grafts, Synthetic Bone Graft Substitutes (Non-Bioactive), Amniotic Membrane-Based Grafts, Exosome-Based Products

What Trends Are Shaping The Orthobiologics Market Structure?

Leading companies in the ornithine transcarbamylase deficiency (OTC Deficiency) market are concentrating on developing innovative treatments, such as mRNA therapeutics, to improve treatment effectiveness and address the root genetic cause of OTC deficiency. mRNA therapeutics represent a class of treatments that employ messenger RNA (mRNA) to direct cells to create specific proteins for therapeutic purposes. These therapies leverage the body’s inherent protein synthesis mechanisms to treat various diseases, including genetic disorders, infectious diseases, and cancers. For instance, in June 2023, Arcturus Therapeutics Holdings Inc., a US-based biotechnology company, secured Fast Track Designation from the U.S. Food and Drug Administration (FDA) for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency. This designation aims to accelerate the drug’s development and review process, potentially offering benefits like more frequent interactions with the FDA and priority review. ARCT-810 is designed to enable patients with OTC deficiency, a urea cycle disorder, to produce functional OTC enzyme in their liver cells, thereby addressing the underlying cause of the condition and potentially enhancing their quality of life.

Who Are The Companies Shaping The Orthobiologics Market Landscape?

Major companies operating in the orthobiologics market are Johnson & Johnson, Medtronic plc, Zimmer Biomet, Arthrex Inc., Integra Lifesciences Corporation, NuVasive Inc., Globus Medical, Bioventus, MTF Biologics, ATEC Spine Inc., Exactech Inc., SeaSpine, RTI Surgical, AlloSource, XTANT MEDICAL, Spine Wave Inc., Bone Biologics Corp., Locate Bio Limited, Wright Medical Group N.V., BoneSupport AB, Graftys, Regenexx, Acumed LLC, Baxter International Inc., LifeNet Health

Access The Complete Orthobiologics Market Report:

https://www.thebusinessresearchcompany.com/report/orthobiologics-global-market-report

Which Regional Market Leads The Orthobiologics Market?

North America was the largest region in the orthobiologics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orthobiologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Orthobiologics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=16139&type=smp

Browse Through More Reports Similar to the Global Orthobiologics Market 2026, By The Business Research Company

Dermatology Otc Medications Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/dermatology-otc-medications-global-market-report

Orthobiologics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/orthobiologics-global-market-report

Oryzanol Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/oryzanol-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795